6533b860fe1ef96bd12c3a7e
RESEARCH PRODUCT
Prostaglandin E(2)-loaded microspheres as strategy to inhibit phagocytosis and modulate inflammatory mediators release.
Peter J. JoseRoberto NicoleteKarla De Melo LimaMaria-jesus SanzMaria-jesus SanzLúcia Helena FaccioliJosé Maciel Rodrigues Júniorsubject
Time Factorsmedicine.medical_treatmentPhagocytosisChemistry PharmaceuticalDrug CompoundingPharmaceutical ScienceInflammationPharmacologyBiologyNitric OxideDinoprostonechemistry.chemical_compoundMiceImmune systemPhagocytosisIn vivoSepsismedicineAnimalsHumansImmunologic FactorsProstaglandin E2Particle SizeCells CulturedChemokine CCL2Tumor Necrosis Factor-alphaEndothelial CellsWaterGeneral MedicineMicrospheresDisease Models AnimalchemistryBiochemistrySolubilityDelayed-Action PreparationsMacrophages PeritonealLiberationlipids (amino acids peptides and proteins)Arachidonic acidEmulsionsmedicine.symptomInflammation MediatorsOilsBiotechnologyProstaglandin Emedicine.drugdescription
PGE(2), an arachidonic acid metabolite produced by various type of cells regulates a broad range of physiological activities in the endocrine, cardiovascular, gastrointestinal, and immune systems, and is involved in maintaining the local homeostasis. In the immune system, PGE(2) is mainly produced by APCs and it can suppress the Th1-mediated immune responses. The aim of this study was to develop PGE(2)-loaded biodegradable MS that prolong and sustain the in vivo release of this mediator. An o/w emulsion solvent extraction-evaporation method was chosen to prepare the MS. We determined their diameters, evaluated the in vitro release of PGE(2), using enzyme immunoassay and MS uptake by peritoneal macrophages. To assess the preservation of biological activities of this mediator, we determined the effect of PGE(2) released from MS on LPS-induced TNF-alpha release by murine peritoneal macrophages. We also analyzed the effect of encapsulated PGE(2) on inflammatory mediators release from HUVECs. Finally, we studied the effect of PGE(2) released from biodegradable MS in sepsis animal model. The use of this formulation can provide an alternative strategy for treating infections, by modulating or inhibiting inflammatory responses, especially when they constitute an exacerbated profile.
year | journal | country | edition | language |
---|---|---|---|---|
2008-11-01 | European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V |